Dicerna Pharmaceuticals — Investor Presentation (January 2020)
27 slides from Dicerna Pharmaceuticals's investor presentation, Jan 13, 2020
Slide 1: Corporate Overview
January 2020 Corporate Overview Exhibit 99.1
Slide 2: Forward-looking statements
This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed o
Slide 3: Dicerna Vision and Strategy
Dicerna Vision and Strategy VISION Develop and commercialize our core high-probability-of-success programs either alone or in collaboration with partners Broadly enable the use of our GalXC™ technology by collaborating with therapeutic area leaders on non-core opportunities STRATEGY Maximize the imp
Slide 4: Dicerna Pipeline of Core and Collaborative Programs
Dicerna Pipeline of Core and Collaborative Programs *Under its agreement with Roche, Dicerna has the option to co-fund pivotal development for heightened royalties and co-promotion rights in U.S. ORPHAN PREVALENT CANDIDATE TARGET INDICATION DISCOVERY/ RESEARCH PRECLINICAL CLINICAL PROOF-OF-CONCEPT T
Slide 5: The Foundation of Our Value: GalXC
Delivery agents Proprietary, patented RNA interference (RNAi) technology with potential to extend to diverse tissues beyond the liver Clinically compelling pharmaceutical properties The Foundation of Our Value GalXC RNAi trigger Subcutaneously delivered ® convenient administration Long duration of a
Slide 6: Multiple Milestones Throughout 2020
Multiple Milestones Throughout 2020 Nedosiran: Multi-dose data from PHYOX™3 open-label clinical trial – 1H 2020 Nedosiran: PHYOX2 pivotal clinical trial enrollment completion – by the end of 1H 2020 DCR-HBVS: Phase 1 proof-of-concept data from all planned cohorts – mid-2020 DCR-A1AT: First patient d
Slide 7: Primary Hyperoxaluria
Primary Hyperoxaluria 7 ©202001cERNA Dicerna”
Slide 8: Primary Hyperoxaluria: ultra-rare, life-threatening genetic disorders
A family of ultra-rare, life-threatening genetic disorders resulting in renal complications Primary Hyperoxaluria (PH) Oxalate Calcium oxalate crystallization Kidney stones Nedosiran Kidney function preservation Known Types of Primary Hyperoxaluria PH1 PH2 PH3 Genetic mutation AGXT Genetic mutation
Slide 9: PHYOX1: 14/18 participants achieved normalization or near-normalization
14/18 participants achieved normalization or near-normalization PHYOX1: Phase 1 Single-Dose Study of Nedosiran in PH1 and PH2 Participants Days After Single Dose Nedosiran Day One 3.0 mg/kg 6.0 mg/kg ≥0.46 & <0.60 near-normal <0.46 normal PHYOX1: Mean Urinary Oxalate Levels by Dose* PHYOX1 open-labe
Slide 10: Nedosiran Clinical Trial Program to NDA Filing
Coordinated program of clinical trials to support a broad label in PH Trial Description/Details Status PH Type Study 201: Pivotal, double-blind, randomized, placebo-controlled trial (2:1 randomization) Monthly fixed-dose, enabling prefilled syringes at launch Enrolling n=~36 1,2 Study 301: Long-term
Slide 11: High unmet medical need across all PH types
High unmet medical need across all PH types can be addressed Nedosiran: The Only RNAi Drug Candidate in Development for All PH Types Genetics of PH PH1 PH2 PH3 All Known PH Types Genetic prevalence (per million) 8.23 5.08 12.58 25.89 US 2,681 1,655 4,098 8,434 EU 2,607 1,609 3,986 8,202 Estimated Pr
Slide 12: Chronic Hepatitis B Virus Infection
Chronic Hepatitis B Virus Infection
Slide 13: Hepatitis B: A Severe, Global Unmet Medical Need
Significant worldwide prevalence: ~292 million infected Causes more than 887,000 deaths per year Current treatments are rarely effective in achieving functional cures Dicerna is collaborating with Roche to develop DCR-HBVS and potentially other agents for the treatment of HBV the treatment Hepatitis
Slide 14: GalXC RNAi May Play a Key Role in Establishing a Functional HBV Cure
Organization of the HBV genome enables effective RNAi targeting of multiple viral functions GalXC RNAi May Play a Key Role in Establishing a Functional HBV Cure The Promise of RNAi for HBV RNAi can simultaneously inhibit multiple viral activities due to overlapping transcripts RNAi can target all vi
Slide 15: Preclinical differences targeting S alone vs. S and X ORFs
Time (weeks) 3mg/kg qWx3 Striking pharmacodynamic differences between targeting in the S alone vs. S and X ORFs in preclinical model Single-Dose GalXC-HBVS Reduced HBsAg to Below Lower Level of Detection GalXC-HBVS: ≥3.9 log reduction, long duration of activity X gene targeted: 3.0 log reduction, sh
Slide 16: DCR-HBVS Clinical Program for Proof of Concept
Includes placebo-controlled studies in both NUC-naïve and NUC-experienced patients Group A Placebo-controlled, single- ascending-dose study Completed n=30 DCR-HBVS dose cohorts: 0.1, 1.5, 3.0, 6.0, 12.0 mg/kg Conducted in healthy volunteers Group B Placebo-controlled, single-dose study in NUC-naïve
Slide 17: Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Slide 18: Single missense allele forms aggregates in hepatocytes
Most disease is caused by a single missense allele that forms aggregates in hepatocytes Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Alpha-1 antitrypsin (A1AT): predominantly produced in liver and secreted into blood Pi*ZZ genotype of the SERPINA1 gene affects 95% of patients with A1AT de
Slide 19: Activity of DCR-A1AT in Mice and Non-Human Primates
Activity of DCR-A1AT in Mice and Non-Human Primates Potency and duration of action Relative Z-AAT Protein Concentration Mean ± SEM Relative A1AT Protein Concentration Mean ± SEM Weeks Post-Dose Single Subcutaneous Dose PBS 3.0 mg/kg 10.0 mg/kg Weeks Post-Dose 3.0 mg/kg 10.0 mg/kg Z-AAT Protein Knock
Slide 20: DCR-A1AT Clinical Program for Proof of Concept
Part of larger clinical plan to achieve a rapid path to approval Two-part study: SAD in healthy volunteers (HVs) and MAD in patients with A1AT deficiency-associated liver disease HVs: Single-ascending-dose study, placebo-controlled, up to 36 patients 5 dose cohorts: 0.1, 1.0, 3.0, 6.0, 12.0 mg/kg, w
Slide 21: Corporate Collaborations
Corporate Collaborations 21 ©202001cERNA Dicerna”
Slide 22: Enhancing Value Through GalXC Collaboration Strategy
Up to 8 cardiometabolic (CM) targets, liver and non-liver Neurodegeneration, pain targets DRNA retains rights to certain neuro orphan indications Successive collaborations increasing in scope and value Enhancing Value Through GalXC Collaboration Strategy Scope, Responsibility, Value 1 NASH target $5
Slide 23: Summary
Summary 23. ©202001CERNA Dicerna”
Slide 24: Elements of Portfolio Strategy
Primary Hyperoxaluria HBV (U.S. opt-in) Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Undisclosed liver program Novo Nordisk program (U.S. opt-ins) Future programs beyond the liver We seek to generate value across the full spectrum of GalXC clinical applications Elements of Portfolio Strat
Slide 25: Strong Cash Position Provides Runway Through Commercialization
Strong Cash Position Provides Runway Through Commercialization Company well capitalized with approximately $350 million in cash (and short-term investments) as of January 1, 2020* including the following amounts received in December 2019: $20 million option exercise payment from Alexion $50 equity i
Slide 26: Multiple Milestones Throughout 2020
Multiple Milestones Throughout 2020 Nedosiran: Multi-dose data from PHYOX™3 open-label clinical trial – 1H 2020 Nedosiran: PHYOX2 pivotal clinical trial enrollment completion – by the end of 1H 2020 DCR-HBVS: Phase 1 proof-of-concept data from all planned cohorts – mid-2020 DCR-A1AT: First patient d
Slide 27: Dicerna
Dicerna’
Dicerna Pharmaceuticals — Investor Presentation (January 2020) on 6ix